ScripAlkermes’s initial release of Phase II trial results for alixorexton in narcolepsy type 1 (NT1) indicates that the company’s drug could prove highly competitive in the growing race among developers of
ScripBristol Myers Squibb is hopeful that it still has a chance to expand the label for Reblozyl (luspatercept-aamt) after a Phase III trial failed to meet the primary endpoint but met several secondary en
ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Debiopharm Gets Global Rights To Repare
In VivoWhen Abbas Kazimi became CEO of Nimbus Therapeutics in March 2025, he didn’t need to introduce a sweeping new three-year vision. After 11 years at the company, having witnessed its evolution from a bo